(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 September 2015 (03.09.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/130813 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2015/017562

(22) International Filing Date:
25 February 2015 (25.02.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/945,737 27 February 2014 (27.02.2014) US

(71) Applicant: **GILEAD BIOLOGICS, INC.** [US/US]; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: **GOSSAGE, David, L.**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **LIN, Joseph, Haw-Ling**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **SMITH, Victoria**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). **VAYSBERG, Maria**; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(74) Agents: **DAMMANN, Yu-Ming** et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

WO 2015/130813 A1

(54) Title: ANTIBODIES TO MATRIX METALLOPROTEINASE 9 AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).